ADXS clearly doesn't want to have to buy the checkpoint-inhibitor supply for the phase-1 HOT trial at full price, so ADXS needs a clinical-trial deal with one of the checkpoint-inhibitor companies.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”